AF
BMRN icon

Arrow Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arrow Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6
Closed -$1K – 377
2015
Q4 		$1K Buy
+6
New +$627 ﹤0.01% 474

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Arrow Financial's BMRN Position: Q1 2016 in Review

Arrow Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 6 shares — an estimated $1K sold.

Arrow Financial first reported a position in BMRN in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

  • Arrow Financial reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Arrow Financial sold 6 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $1K.
  • Arrow Financial first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Arrow Financial's BioMarin Pharmaceuticals position peaked at $1K in Q4 2015.
  • 390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Arrow Financial's 13F filing for Q1 2016, filed 4 May 2016.